Diagnostic News and Research

RSS

RadNet second-quarter revenue increases 6.0% to $139.0 million

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 191 fully-owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2010.

9 Aug 2010

Aquilion ONE 320-detector row CT system reduces radiation exposure

When pediatric patients are imaged using CT, reducing sedation and radiation dose while maintaining the best possible image quality is paramount in delivering care. To provide patients with high-quality CT exams and a reduction in sedation and radiation dose, leading children's hospitals are installing Toshiba America Medical Systems, Inc.'s Aquilion ONE 320-detector row CT system.

9 Aug 2010

Myconostica announces CE marking for MycAssay Aspergillus and Pneumocystis on additional platforms

Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the CE marking of its lead products MycAssay™ Aspergillus and MycAssay™ Pneumocystis on the Roche Lightcycler® 2.0 and Stratagene Mx3000 series platforms.

9 Aug 2010

45-year-old Hummelstown patient takes on FDA over Johnson & Johnson’s antibiotic Levaquin

Suffering from injuries to his brain, nerves, and tendons for over four years, 45-year-old John Fratti of Hummelstown, PA, has taken on the Food and Drug Administration with good results. Since taking Johnson & Johnson’s antibiotic Levaquin for an infection he has had many diagnostic studies on his brain and body that show considerable damage. Healthy and athletic at 41 years of age, he now takes multiple prescription pain medications for his injuries.

7 Aug 2010

Robertson Global Health Solutions reports completion of name change and reverse stock split

Robertson Global Health Solutions Corporation announced today that it has formally completed its name change along with a 1 for 15 reverse stock split resulting in 11,543,346 shares of common stock currently issued and outstanding with 20,000,000 shares, par value $0.001, authorized. The Company also has 1,000,000 shares of preferred stock authorized, par value $0.001, with no preferred shares outstanding.

7 Aug 2010

Response Genetics total revenue for second-quarter 2010 increases 197% to $5.6 million

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three and six months ended June 30, 2010.

7 Aug 2010

Akonni Biosystems receives patent for TruTip Extraction Kits

Akonni Biosystems, a developer of low-cost, multiplex molecular diagnostic testing systems, today announced that the United States Patent and Trademark Office issued a patent on July 20, 2010 for its method for rapidly purifying nucleic acids. U.S. Patent No. 7,759,112 entitled, "Apparatus, system, and method for purifying nucleic acids" protects the Company's use of its pioneering nucleic acid binding matrix when inserted into a pipette tip, tubing or cartridge for nucleic acid purification. The patent is owned by Akonni Biosystems.

6 Aug 2010

Split-dosage method effective for bowel cleansing before colonoscopy: Study

A new study from researchers in Italy has found that a split-dosage schedule of bowel (colon) preparation is the most effective method for bowel cleansing before colonoscopy. Colonoscopies performed within six to eight hours of the end of preparation were associated with significantly better cleansing than those performed more than eight hours after the end of preparation. Two different types of bowel cleansing products were also assessed and researchers found that low-volume polyethylene glycol (PEG) plus ascorbic acid was as effective as high-volume PEG-electrolyte solution, but has superior palatability (or taste). This is the first study to demonstrate that the advantage of split-dosage intake is also true for low-volume bowel cleansing solutions.

6 Aug 2010

SeraCare optimizes ACCURUN 341 Nucleic Acid Positive controls

SeraCare Life Sciences, Inc. today announced that the Company has developed a new series of controls in its ACCURUN portfolio to monitor and validate molecular diagnostic test performance for detection of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG). Through collaboration with instrument and reagent manufacturers, SeraCare has optimized the ACCURUN 341 Nucleic Acid Positive controls specifically for use with the three most popular assays currently on the market; the Gen-Probe APTIMA Combo 2 Assay, the Roche COBAS AMPLICOR CT/NG Test, and the Becton, Dickinson BD ProbeTec ET System.

6 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Beckman Coulter announces contract with CML for high quality diagnostic services

Beckman Coulter, Inc., a leading developer, manufacturer, and marketer of products that simplify, automate, and innovate complex biomedical testing, today announced a record contract with CML HealthCare of Toronto, Canada. According to the company, the deal represents the largest contract of any Canadian diagnostics company for a single testing site.

From Beckman Coulter Diagnostics 5 Aug 2010

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.

5 Aug 2010

AG Mednet receives patent for diagnostic imaging studies

AG Mednet, the world's largest diagnostic imaging network, announced today that the U.S. Patent Office had granted the company patent number 7765109, "Systems and methods for providing diagnostic imaging studies to one or more interpreters and selecting one or more of the interpreters to provide an interpretation of the images based on one or more variables." The patent broadly encompasses a number of key innovations in the field, all of which are made a reality for the first time by AG Mednet to all its users worldwide.

5 Aug 2010

EEG patterns can predict schizophrenia patients' response to clozapine therapy

A commonplace electroencephalography (EEG) test may hold the key to predicting whether a person will respond to certain prescribed drugs, particularly those related to psychiatric conditions.In a study to be published by Clinical Neurophysiology, and now posted online, engineering and health sciences researchers at McMaster University applied machine learning to EEG patterns and successfully predicted how patients with schizophrenia would respond to clozapine therapy.

5 Aug 2010

Detection of Alzheimer's before symptoms occur

Research is on to detect the dreaded Alzheimer's disease even before any symptoms occur. In a newly proposed diagnostic criteria developed by experts from the National Institute on Aging and the Alzheimer's Association three stages of the disease viz. pre-clinical Alzheimer's, mild cognitive impairment and Alzheimer's dementia are described.

4 Aug 2010

Fractures are major concern for U.S. high school athletes: Study

The popularity of high school sports in the United States has continued to increase over the past decade, with more than 7.5 million athletes participating in school sports during the 2008-09 academic year. A new study conducted by the Center for Injury Research and Policy of The Research Institute at Nationwide Children's Hospital found that 95 percent of fractures required costly diagnostic imaging, including X-rays, MRIs and CT scans, and 16 percent required surgical repair.

4 Aug 2010

New perfusion CT algorithms maintain image quality at half of the radiation dose

In recent years, advances in CT scanner technology have made perfusion computed tomography (CT) imaging an important diagnostic tool for patients with suspected stroke. Now, researchers at Mayo Clinic are working to reduce radiation dosages used to acquire perfusion and other CT images. Mayo Clinic medical physicist Cynthia McCollough, Ph.D., and her group of researchers presented their findings related to CT dose reduction at the 52nd Annual Meeting of the American Association of Physicists in Medicine on July 20 in Philadelphia.

4 Aug 2010

New MIC platform measures cell-signaling pathways in brain tumor samples at single-cell level

New technologies for the diagnosis of cancer are rapidly changing the clinical practice of oncology. As scientists learn more about the molecular basis of cancer, the development of new tools capable of multiple, inexpensive biomarker measurements on small samples of clinical tissue will become essential to the success of genetically informed and personalized cancer therapies.

4 Aug 2010

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

Biotechnology company MabCure, Inc. today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure's tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women.

4 Aug 2010

IL releases new HemosIL HIT-Ab(PF4-H) assay

Instrumentation Laboratory (IL) today announced the release of the new HemosIL HIT-Ab(PF4-H) assay as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. Delivering results in minutes, the HemosIL HIT-Ab(PF4-H) assay detects total immunoglobulin against Platelet Factor 4-Heparin complexes, the antibodies associated with the pathology of HIT.

4 Aug 2010

Diagnostic News and Research

RadNet second-quarter revenue increases 6.0% to $139.0 million

Aquilion ONE 320-detector row CT system reduces radiation exposure

Myconostica announces CE marking for MycAssay Aspergillus and Pneumocystis on additional platforms

45-year-old Hummelstown patient takes on FDA over Johnson & Johnson’s antibiotic Levaquin

Robertson Global Health Solutions reports completion of name change and reverse stock split

Response Genetics total revenue for second-quarter 2010 increases 197% to $5.6 million

Akonni Biosystems receives patent for TruTip Extraction Kits

Split-dosage method effective for bowel cleansing before colonoscopy: Study

SeraCare optimizes ACCURUN 341 Nucleic Acid Positive controls

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Beckman Coulter announces contract with CML for high quality diagnostic services

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

AG Mednet receives patent for diagnostic imaging studies

EEG patterns can predict schizophrenia patients' response to clozapine therapy

Detection of Alzheimer's before symptoms occur

Fractures are major concern for U.S. high school athletes: Study

New perfusion CT algorithms maintain image quality at half of the radiation dose

New MIC platform measures cell-signaling pathways in brain tumor samples at single-cell level

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

IL releases new HemosIL HIT-Ab(PF4-H) assay

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News